Purchase the ATMP report at www.evernowpublishing.com

Subscribe to MedNous and get ahead in the business of medical innovation. Subscribe now.

The latest MedNous journal. Subscribe to download.

Keytruda approved for multiple solid tumours

Country: United States

Merck & Co Inc’s checkpoint inhibitor Keytruda (pembrolizumab) has been approved in the US for multiple solid tumours that have a common genetic feature known as microsatellite instability-high or mismatch repair deficit.

Read more

Zykadia gets new lung cancer indication

Country: Switzerland

The Novartis tyrosine kinase inhibitor Zykadia (ceritinib) has been approved in the US for the first-line treatment of ALK-positive non-small cell lung cancer following Phase 3 data that showed a significant improvement in progression free survival in patients with the disease.

Read more

Epidiolex has positive Phase 3 results

Country: United Kingdom

Read more

Argenx makes its New York debut

Country: Belgium

Read more

Vertex gets regulatory nod

Country: United States

Read more

Money for Italian biotech

Country: Italy

Read more

Celyad licenses technology to Novartis

Country: Belgium

Read more

Adaptimmune funded through to late 2019

Country: United Kingdom

Read more

Immunocore identifies new lead compound

Country: United Kingdom

Read more

Takeda takes option on GammaDelta

Country: United Kingdom

Read more

Pfizer in gene therapy deal

Country: United States

Read more

Ablynx awaits regulatory decision

Country: Belgium

Read more

Looking for more?

Visit our news section for more articles.

News
Our full Mednous news archive
Appointments
Latest industry appointments
Events
A list of upcoming industry events

About Mednous

MedNous is a print publication and a website for everyone involved in medical research in Europe.

Read more

Free Article

How Pharma is targeting checkpoint inhibitors by Bruno Pagliara

OncologyReviewCheckpointInhibitorsMay2017.pdf

Highlights of the April 2017 MedNous issue

The April 2017 MedNous features:

Latest Mednous cover
  • Research Strategy
    Drugs for orphan diseases are no longer rare
    By Robin Davison
  • Public Policy
    Challenging orthodoxy on drug pricing
  • Commentary
    Why patient-reported outcomes matter
    By Andy Smith
  • Stock market performance
    European biotechs climb to the top of the tree
  • Commentary
    Is an EU approval better than a hospital exemption?
    By Tim Farries

The latest MedNous journal. Subscribe to download.